Head-to-head · WeighScore
Midi Health vs Tell Her Doc
The verdict
Tell Her Doc takes it — 57.2/100 to 56.4/100, but only just.
Tell Her Doc grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Tell Her Doc is a women-focused, self-pay telehealth program for compounded GLP-1 weight loss — compounded semaglutide and tirzepatide in injection, oral, and orally-dissolving-tablet forms, plus microdoses. Midi Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Midi Health | Tell Her Doc |
|---|---|---|
| WeighScore | 56.4/100 | 57.2/100 |
| Grade | C | C |
| Scorecard rank | #414 | #404 |
| Semaglutide | Not disclosed | $269/mo (microdose tier, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #414 · C
Strengths
- Available in all 50 states
- Accepts commercial insurance — a differentiator vs cash-pay-only GLP-1 telehealth
- Menopause + metabolic-health focus suits women where GLP-1 efficacy and weight regulation overlap most
- Transparent self-pay visit fees ($250 initial, $150 follow-up); GLP-1 can also be billed through commercial insurance (copay + deductible)
Where it loses points
- Does not accept Medicare, Medicaid, or Medi-Cal
- GLP-1 is prescribed at clinician discretion within a menopause plan, not guaranteed at intake
- Menopause-focused — not the right fit for men or younger women whose main goal is weight loss
Graded #404 · C
Strengths
- Full compounded GLP-1 lineup — semaglutide and tirzepatide in injection, oral and orally-dissolving-tablet forms, plus microdoses
- Names its compounding pharmacy partner (Casa Pharma RX), which is independently listed in our pharmacy registry
- No monthly membership, cancel anytime, free discreet shipping; HSA/FSA eligible with buy-now-pay-later plans
- Serves patients in all 50 states via a private online consultation
Where it loses points
- 'All sales are final' — no refunds once medication has left the pharmacy
- Exact price is plan-dependent, shown after you pick a product; advertised 'starting at $269', with a lower $140 intro on oral semaglutide
- References LegitScript but without an independently verifiable seal — we couldn't confirm certification
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.